Novocure Ltd Equity-NMS: NVCR

Healthcare

Medical Devices

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :	$14.72
Open :	$14.68
Today's high :	$14.85
Today's low :	$14.5
52W low :	$10.87
52W high :	$24.735
1Y :	2.36%
5Y :	-79.84%
EPS(TTM): :	-1.58
Shares O/S :	108.22 M
Market cap :	1.58 B

What is the share price of Novocure Ltd today?

Novocure Ltd (NVCR) share price as of October 8, 2024, is $14.62. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Novocure Ltd?

Yes, Indian Investors can invest in the Novocure Ltd (NVCR) Share by opening an international trading account with Angel One.

How can I purchase Novocure Ltd shares in India?

Purchasing Novocure Ltd (NVCR) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Novocure Ltd (NVCR) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Novocure Ltd?

Yes, you can purchase fractional shares of Novocure Ltd (NVCR) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Novocure Ltd?

The market capitalization of Novocure Ltd on October 8, 2024, is $1.58 B.

In which sector Novocure Ltd belongs?

Novocure Ltd operates in the Healthcare sector, specifically in the Medical Devices industry.

What documents are required to invest in Novocure Ltd stocks?

In order to invest in Novocure Ltd (NVCR) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.